Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...

Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lillyand Co., American Express Co ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), American ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

The UC space is highly diversified with a number of molecules approved. In October 2023, the FDA approved Omvoh (mirikizumab), an interleukin-23 antagonist developed by Eli Lilly. It is indicated ...

(Annals of Internal Medicine) A small case series published in Inflammatory Bowel Diseases showed that patients with moderately active ulcerative colitis can benefit from mirikizumab (Omvoh ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Lilly markets its dual GIP and GLP-1 receptor agonist ...

Eli Lilly’s Omvoh became the first IL-23 drug approved in ulcerative colitis in October 2023, while AbbVie’s Skyrizi hit the scene as the first IL-23 med cleared by the FDA to treat Crohn’s ...

as well as approval for Omvoh to treat moderately to severely active Crohn’s disease. It is one of the best high growth stocks to buy as the company has grown its revenue by over 15% in the past ...